|Bid||50.37 x 3100|
|Ask||51.20 x 800|
|Day's Range||51.10 - 52.68|
|52 Week Range||31.97 - 64.48|
|Beta (3Y Monthly)||1.15|
|PE Ratio (TTM)||4.36|
|Earnings Date||Nov 5, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||69.00|
EVP, General Counsel & Sec of Arena Pharmaceuticals Inc (30-Year Financial, Insider Trades) Steven W Spector (insider trades) sold 44,084 shares of ARNA on 09/10/2019 at an average price of $50.59 a share. Continue reading...
SAN DIEGO, Sept. 9, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) presented new patient-reported outcomes data for olorinab, an investigational, oral, peripherally acting, highly-selective, full agonist of the cannabinoid receptor 2 (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) disorders, at the European Society of Neurogastroenterology & Motility (ESNM) 2019 NeuroGASTRO Meeting. Etrasimod (APD334), with potential utility in a broad range of immune and inflammatory conditions, is being evaluated in later-stage clinical programs in ulcerative colitis (UC) and Crohn's disease (CD), as well as in programs for other indications such as atopic dermatitis.
Amit Munshi became the CEO of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in 2016. First, this article will compare CEO...
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.
SAN DIEGO , Aug. 28, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in the upcoming investor conferences: Wells ...
What are the biggest marijuana companies in the world? If you are looking for the safest investment, marijuana companies may just be the next big thing. Were we to pinpoint one industry which is sure to continue blooming in the future, both near and distant, that would be precisely this one - a multi-billion business […]
Investors punished biotech companies Sarepta Therapeutics and Arena Pharmaceuticals on growing losses in the second quarter, and lauded Aerie Pharmaceuticals for its guidance cut.
- Etrasimod initiation of the Phase 3 ELEVATE UC 52 global trial in ulcerative colitis (UC) - Olorinab initiation of the Phase 2 CAPTIVATE clinical trial in abdominal pain associated with irritable bowel ...
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
United Therapeutics (UTHR) beats estimates on both fronts in the second quarter. Loss of exclusivity for Adcirca and lower sales of Remodulin hurts sales.
SAN DIEGO , July 31, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2019 financial results and provide a corporate update on Wednesday, August 7, 2019 ...
Arena Pharmaceuticals (ARNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arena Pharmaceuticals (ARNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
SAN DIEGO, July 25, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that the first subject has been dosed in the Phase 2 CAPTIVATE trial evaluating olorinab, an investigational, oral, highly-selective, full agonist of the cannabinoid type 2 receptor (CB2) in development for the treatment of visceral pain associated with gastrointestinal (GI) disorders. The trial will evaluate the efficacy and safety of three dose levels of olorinab for 12-weeks in approximately 240 subjects experiencing abdominal pain associated with IBS, including IBS with constipation (IBS-C) or IBS with diarrhea (IBS-D). "I am thrilled that the first subject has enrolled in Arena's CAPTIVATE trial, supporting the advancement of novel pain management options within the digestive disease field," said Lin Chang, MD, Professor of Medicine at the Vatche and Tamar Manoukian Division of Digestive Diseases at the University of California, Los Angeles.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a stock with outstanding fundamental characteristics. When we build an...
Arena (ARNA) doses first patient in one of the two pivotal late-stage studies evaluating its pipeline candidate, etrasimod in ulcerative colitis indication.
SAN DIEGO, June 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that the first subject has been dosed in ELEVATE UC 52, the first of two pivotal trials within the Phase 3 ELEVATE UC registrational program evaluating etrasimod 2 mg in subjects with moderately to severely active ulcerative colitis (UC). ELEVATE UC 52 is a treat-through trial with a 12-week induction period followed by 40 weeks of maintenance.
The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
SAN DIEGO, June 13, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019, at 1:30 PM EDT. A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. Arena Pharmaceuticals is driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally.